{"schema_version":"secwatch.filing_event.v1","accession":"0001595585-23-000023","form_type":"8-K","ticker":null,"cik":"0001595585","company_name":"Tricida, Inc.","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.760170+00:00","generated_at":"2026-06-18T02:02:09.408605+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tricida completes sale of Veverimer to Renibus for $250K upfront + up to $152.5M milestones","bullets":["Asset sale closed March 9, 2023 after Bankruptcy Court approval on Feb 22.","Upfront cash payment of $250,000; contingent milestones tied to FDA approval and net sales up to $152.5M.","Company remains in Chapter 11 proceedings (Case No. 23-10024).","Veverimer (TRC101) was Tricida's lead drug candidate for chronic kidney disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001595585-23-000023","json":"https://secwatch.observer/filing/0001595585-23-000023.json","markdown":"https://secwatch.observer/filing/0001595585-23-000023.md","text":"https://secwatch.observer/filing/0001595585-23-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595585/000159558523000023/0001595585-23-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595585/000159558523000023/tcda-20230309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T02:02:09.408605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6acd157c5d71428b775f622fd2a4452e8455054e","claim":"Tricida, Inc. completed a disposition involving Renibus Therapeutics, Inc. for $250,000 at closing and certain contingent, milestone payments to the Company totaling up to $152.5 million (closed 2023-03-09).","evidence_excerpt":"agreed to acquire the intellectual property, inventory, and certain related assets relating to Veverimer (formerly known as TRC101) (the “Compound”) for a cash payment of $250,000 at closing and certain contingent, milestone payments to the Company totaling up to $152.5 million, subject to the achievement of certain United States Food and Drug","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595585/000159558523000023/0001595585-23-000023-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Renibus Therapeutics, Inc."},{"label":"Consideration","value":"$250,000 at closing and certain contingent, milestone payments to the Company totaling up to $152.5 million"},{"label":"Closing","value":"2023-03-09"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}